Follow

Interviews with CEO Hans Arwidsson

11 June 2021 - 07:50

Eurocine Vaccines AB has published two interviews with CEO Hans Arwidsson in connection with the ongoing preferential issue of units. The interviews, which have partly different content, are in writing and in English and Swedish, respectively.

For interview in English, please see:

Interview with CEO Hans Arwidsson at IPOhub

For interview in Swedish, please see:

Interview with CEO Hans Arwidsson at Stockpicker

Hans Arwidsson, Ph.D., MBA

CEO of Eurocine Vaccines AB
[email protected]

+46 70 634 0171

Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.

Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.

The company is in the possession of its own technology platform, Endocine™, which has been tested in four extensive clinical studies with over 400 subjects.

Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.

Provided by: Cision
Spotlight Stock Market (Sweden)
Eurocine Vaccines AB
Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market. Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization. The com...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More